Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search

 


Direct Capital acquires 51% of NZ Pharmaceuticals

Direct Capital acquires 51% of New Zealand Pharmaceuticals

Leading private equity firm Direct Capital has acquired a shareholding of 51% in New Zealand Pharmaceuticals (NZP), which produces specialty chemicals for some of the world's leading pharmaceutical and biotechnology companies.

Direct Capital's investment has been completed from its DCPIII and Pohutukawa private equity funds and from BioPacificVentures (BPV), allowing Direct Capital to combine its traditional private equity strength with BPV's specialist industry expertise.

The remaining 49% of NZP will continue to be owned by the management and staff of NZP and strategic investor Shin Nippon Yakugyo, a Japanese specialty chemicals business.

NZP manufactures pharmaceutical intermediates and diagnostics and also produces a range of ingredients used in dietary supplements. NZP's core competence is in the manufacture of natural biochemicals under Good Manufacturing Practice (GMP) conditions which ensures its products conform to pharmaceutical industry quality assurance standards. Almost all of NZP's revenues are achieved from export markets.

The company's main product, cholic acid, is manufactured from bovine bile and is an intermediate for a drug used to treat liver related diseases. Other animal based products include taurine, an amino acid used in infant formula, heparin, a blood anticoagulant and ferritin, a natural iron supplement.

One of NZP's more recent product initiatives is 'ManNAc', the first of what NZP hopes will be a number of synthetic compounds produced for the manufacture of glycotherapeutic drugs, a large fast growing category of the global pharmaceuticals market and of increasing significance to NZP's business. NZP's role in this area has developed from its relationship with Industrial Research Ltd, which is developing a range of these specialty carbohydrates of interest to the international biotechnology industry. Financing for Direct Capital's acquisition includes the capital expenditure funding required by NZP to build a new factory to manufacture these glycotherapeutic intermediates. Construction is scheduled for 2006 on the site of the existing head office and manufacturing plant in Linton near Palmerston North.

Tony Batterton and Howard Moore (representing Direct Capital) will join management representatives on the NZP Board and a new independent chairman will also be appointed shortly.

Richard Garland, NZP Managing Director, commented that "Direct Capital bring a wealth of experience in supporting the development of growing businesses like NZP and, in BiopacificVentures, people and strategic partners with considerable experience in the markets in which NZP operates. The investment by Direct Capital is an important pre-cursor to the planned public listing of NZP, which we are targeting within the next three years. This is an exciting and positive development for NZP and our shareholders."

Ross George, Managing Director of Direct Capital, said that "NZP is an extremely well positioned company, with an excellent team of people and attractive growth opportunities in all of its areas of operation. We look forward to working with the management and employees to continue the company's success."

© Scoop Media

 
 
 
 
 
Business Headlines | Sci-Tech Headlines

 

Watch This Space: Mahia Rocket Lab Launch Site Officially Opened

Economic Development Minster Steven Joyce today opened New Zealand’s first orbital launch site, Rocket Lab Launch Complex 1, on the Mahia Peninsula on the North Island’s east coast. More>>

Earlier:

Marketing Rocks!
Ig Nobel Award Winners Assess The Personality Of Rocks

A Massey University marketing lecturer has received the 2016 Ig Nobel Prize for economics for a research project that asked university students to describe the “brand personalities” of three rocks. More>>

ALSO:

Nurofen Promotion: Reckitt Benckiser To Plead Guilty To Misleading Ads

Reckitt Benckiser (New Zealand) intends to plead guilty to charges of misleading consumers over the way it promoted a range of Nurofen products, the Commerce Commission says. More>>

ALSO:

Half A Billion Accounts, Including Xtra: Yahoo Confirms Huge Data Breach

The account information may have included names, email addresses, telephone numbers, dates of birth, hashed passwords (the vast majority with bcrypt) and, in some cases, encrypted or unencrypted security questions and answers. More>>

ALSO:

Rural Branches: Westpac To Close 19 Branches, ANZ Looks At 7

Westpac confirms it will close nineteen branches across the country; ANZ closes its Ngaruawahia branch and is consulting on plans to close six more branches; The bank workers union says many of its members are nervous about their futures and asking ... More>>

Interest Rates: RBNZ's Wheeler Keeps OCR At 2%

Reserve Bank governor Graeme Wheeler kept the official cash rate at 2 percent and said more easing will be needed to get inflation back within the target band. More>>

ALSO:

Get More From Scoop

 
 
 
 
 
 
 
 
 
Business
Search Scoop  
 
 
Powered by Vodafone
NZ independent news